Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy M Miller

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosisTimothy M Miller, Soo H Kim, Koji Yamanaka, et al.
Elife|October 19, 2020
Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2AAntonietta Franco, Xiawei Dang, Emily K Walton, et al.
Muscle & Nerve|October 29, 2020
Smartphone data during the COVID-19 pandemic can quantify behavioral changes in people with ALSAnna L Beukenhorst, Ella Collins, Katherine M Burke, et al.
Immunology|May 12, 2018
MicroRNA signature of central nervous system-infiltrating dendritic cells in an animal model of multiple sclerosisMariah L Hoye, Angela S Archambault, Taylor M Gordon, et al.
JMIR Mhealth and Uhealth|February 4, 2022
Using Smartphones to Reduce Research Burden in a Neurodegenerative Population and Assessing Participant Adherence: A Randomized Clinical Trial and Two Observational StudiesAnna L Beukenhorst, Katherine M Burke, Zoe Scheier, et al.
JAMA Neurology|October 17, 2022
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A ReviewJeremy M Shefner, Richard Bedlack, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
Plos Biology|March 24, 2026
A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanismsLohany Dias Mamede, Miwei Hu, Jaime Vaquer-Alicea, et al.
Annals of Neurology|December 27, 2025
Neurofilament Proteoforms in Amyotrophic Lateral Sclerosis Are Different in Cerebrospinal Fluid and BloodJohn B Coulton, Yingxin He, Melissa M Budelier, et al.
Nature Reviews. Drug Discovery|February 6, 2024
The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseasesP J Brooks, Timothy M Miller, Frédéric Revah, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosisTimothy M Miller, Soo H Kim, Koji Yamanaka, et al.
Elife|October 19, 2020
Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2AAntonietta Franco, Xiawei Dang, Emily K Walton, et al.
Muscle & Nerve|October 29, 2020
Smartphone data during the COVID-19 pandemic can quantify behavioral changes in people with ALSAnna L Beukenhorst, Ella Collins, Katherine M Burke, et al.
Immunology|May 12, 2018
MicroRNA signature of central nervous system-infiltrating dendritic cells in an animal model of multiple sclerosisMariah L Hoye, Angela S Archambault, Taylor M Gordon, et al.
JMIR Mhealth and Uhealth|February 4, 2022
Using Smartphones to Reduce Research Burden in a Neurodegenerative Population and Assessing Participant Adherence: A Randomized Clinical Trial and Two Observational StudiesAnna L Beukenhorst, Katherine M Burke, Zoe Scheier, et al.
JAMA Neurology|October 17, 2022
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A ReviewJeremy M Shefner, Richard Bedlack, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
Plos Biology|March 24, 2026
A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanismsLohany Dias Mamede, Miwei Hu, Jaime Vaquer-Alicea, et al.
Annals of Neurology|December 27, 2025
Neurofilament Proteoforms in Amyotrophic Lateral Sclerosis Are Different in Cerebrospinal Fluid and BloodJohn B Coulton, Yingxin He, Melissa M Budelier, et al.
Nature Reviews. Drug Discovery|February 6, 2024
The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseasesP J Brooks, Timothy M Miller, Frédéric Revah, et al.
Pageof 13